Status:
UNKNOWN
Safety and Superiority of Penicillamine in Radiosensitization of Recurrent Head and Neck Cancer
Lead Sponsor:
Nanfang Hospital, Southern Medical University
Conditions:
Head and Neck Cancer
Recurrent Cancer
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
Our preclinical study confirmed that copper accumulation can lead to radioresistance in vitro and in vivo, and reducing the concentration of copper with copper chelator help to overcome radioresistanc...
Detailed Description
Head and neck cancer is the sixth most common cancer worldwide. Radiotherapy is an important measure to control tumor recurrence. Although radiotherapy has been widely used in patients with head and n...
Eligibility Criteria
Inclusion
- Sign informed consent
- The age is 18-75 years
- Previously received standard radical radiotherapy or chemoradiotherapy
- Head and neck tumors with in situ or cervical lymph node recurrence confirmed by pathological biopsy and imaging examination
- ECOG PS：0/1
- Laboratory examination confirmed good organ function, which should be carried out within 10 days before the first treatment.
Exclusion
- After evaluation, it does not meet the indications of re-radiotherapy
- Unable to take oral medication
- Pregnancy or lactation
- Known allergy to penicillamine
- Patients who are judged by the researcher as unsuitable to participate in this trial.
Key Trial Info
Start Date :
November 15 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2025
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT06103617
Start Date
November 15 2023
End Date
June 1 2025
Last Update
November 18 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Southern medical university
Guangzhou, Guangdong, China, 510515
2
Nanfang Hospital, Sourthern Medical University
Guangzhou, China